Due to health issues, this site is no longer maintained and will be shut down shortly.

PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics, Inc. is a biotechnology company, which specializes in the discovery and development of therapeutics to treat central nervous system disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

$1.95  +0.21 (12.07%)
As of 03/24/2023 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/18/1996
Outstanding shares:  17,209,612
Average volume:  13,819
Market cap:   $29,944,725
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy